Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.

  title={Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.},
  author={Olivia S Chao and Oscar B. Goodman},
  journal={Molecular cancer research : MCR},
  volume={12 12},
UNLABELLED Tumors with BRCA germline mutations are defective in repairing DNA double-strand breaks (DSB) through homologous recombination (HR) pathways, making them sensitive to PARP inhibitors (PARPi). However, BRCA germline mutations are rare in prostate cancer limiting the ability to therapeutically target these pathways. This study investigates whether histone deacetylase (HDAC) inhibitors (HDACi), reported to modulate DSB repair pathways in sporadic cancers, can downregulate DSB repair… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 50 references

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

Proceedings of the National Academy of Sciences of the United States of America • 2005
View 10 Excerpts
Highly Influenced

Downregulation of homologous recombination Combined HDAC and PARP Inhibition in Prostate Cancer Cells Mol Cancer Res

SK Kachhap, N Rosmus, +3 authors M Hedayati
December 2014 1765 on June • 2014
View 2 Excerpts

Cancer statistics, 2013.

CA: a cancer journal for clinicians • 2013

Panobinostat, an oral pan-histone deacetylase (HDAC) inhibitor activates a microrna signature that targets Rad51 to attenuate homologous DNA repair and sensitize AML cells to sapacitabine

D Sampath, A Zecevic, +3 authors G Marcucci
Blood • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…